Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1976 1
1977 1
1978 2
1979 1
1981 3
1982 5
1983 3
1984 4
1985 1
1986 1
1987 1
1988 1
1989 3
1990 4
1991 2
1992 2
1993 7
1994 5
1995 3
1996 4
1997 5
1998 1
1999 3
2000 9
2001 4
2002 8
2003 5
2004 4
2005 3
2006 3
2007 6
2008 4
2009 8
2010 6
2011 10
2012 33
2013 17
2014 9
2015 7
2016 6
2017 4
2018 4
2019 3
2020 6
2021 3
2022 6
2023 13
2024 15
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. The EMPA-KIDNEY Collaborative Group, et al. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. N Engl J Med. 2023. PMID: 36331190 Free PMC article. Clinical Trial.
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Zhu D, Dayanandan R, Arimoto R, Mayne KJ, Ng SYA, Sammons E, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney DZI, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Brueckmann M, Landray MJ, Baigent C, Haynes R; EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group, et al. N Engl J Med. 2025 Feb 20;392(8):777-787. doi: 10.1056/NEJMoa2409183. Epub 2024 Oct 25. N Engl J Med. 2025. PMID: 39453837 Free PMC article. Clinical Trial.
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Mayne KJ, Sardell RJ, Staplin N, Judge PK, Zhu D, Sammons E, Cherney DZI, Cheung AK, Maggioni AP, Nangaku M, Rossello X, Tuttle KR, Ihara K, Iwata T, Wanner C, Emberson J, Preiss D, Landray MJ, Baigent C, Haynes R, Herrington WG; EMPA-KIDNEY Collaborative Group. Mayne KJ, et al. Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1119-1129. doi: 10.2215/CJN.0000000000000498. Epub 2024 Jun 27. Clin J Am Soc Nephrol. 2024. PMID: 40179340 Free PMC article. Clinical Trial.
Mediastinal omentoplasty.
Seman M, Bouchet-Doumenq C, Kirhch M, Menegaux F, Trésallet C. Seman M, et al. J Visc Surg. 2013 Apr;150(2):109-14. doi: 10.1016/j.jviscsurg.2013.03.009. Epub 2013 Apr 11. J Visc Surg. 2013. PMID: 23582216 Free article. No abstract available.
The alarmin, interleukin-33, increases vascular tone via extracellular signal regulated kinase-mediated Ca2+ sensitization and endothelial nitric oxide synthase inhibition.
DeVallance E, Bowdridge E, Garner K, Griffith J, Seman M, Batchelor T, Velayutham M, Goldsmith WT, Hussain S, Kelley EE, Nurkiewicz TR. DeVallance E, et al. Among authors: seman m. J Physiol. 2024 Nov;602(22):6087-6107. doi: 10.1113/JP286990. Epub 2024 Nov 14. J Physiol. 2024. PMID: 39540837 Free article.
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Zhou J, Williams C, Staplin N, Judge PK, Mayne KJ, Agrawal N, Arimoto R, Green JB, Cherney DZI, Tuttle KR, Leal J, Clarke P, Emberson JR, Preiss D, Wanner C, Landray MJ, Baigent C, Haynes R, Herrington WG, Mihaylova B; EMPA-KIDNEY Collaborative Group. Zhou J, et al. EClinicalMedicine. 2025 Jul 8;85:103338. doi: 10.1016/j.eclinm.2025.103338. eCollection 2025 Jul. EClinicalMedicine. 2025. PMID: 40686671 Free PMC article.
Extracellular NAD(+): a danger signal hindering regulatory T cells.
Adriouch S, Haag F, Boyer O, Seman M, Koch-Nolte F. Adriouch S, et al. Among authors: seman m. Microbes Infect. 2012 Nov;14(14):1284-92. doi: 10.1016/j.micinf.2012.05.011. Epub 2012 May 24. Microbes Infect. 2012. PMID: 22634347 Free article. Review.
255 results